Print PDF
Axinn's Partner Chad A. Landmon Quoted by The Pink Sheet Discussing the Lovenox Lawsuit
August 2, 2010

Sanofi-Aventis’ suit against FDA seeking to overturn its approval of generic Lovenox is an example of what FDA will face once it approves follow-on biologics. Lovenox is not a biologic, however, it is a complex compound that raises some of the same issues as biosimilars. Chad Landmon, Partner at Axinn, told The Pink Sheet, “I think similar arguments will be litigated with respect to follow-on biologics. One of the initial disputes at FDA and in the courts [will be whether a biologic] molecule is so large we don’t know what the innovator product is.”

The article, titled “Lovenox Lawsuit May Be Omen For Biosimilar Battles,” was filed August 2, 2010, by The Pink Sheet

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.